Glenmark is struggling with high debt, lack of meaningful approvals to shore-up declining US sales and delays in commercialization of specialty anti-allergy nasal spray Ryaltris.from Moneycontrol Business News https://ift.tt/2Z6CCrg
Friday, August 16, 2019
Glenmark Pharma pins hope on sale of non-core assets, IPO of spun-off RD unit to pare debt
Glenmark is struggling with high debt, lack of meaningful approvals to shore-up declining US sales and delays in commercialization of specialty anti-allergy nasal spray Ryaltris.from Moneycontrol Business News https://ift.tt/2Z6CCrg
Subscribe to:
Post Comments (Atom)
-
The value had touched a high of 22% of total market capitalisation of listed firms in June 2009, dropping to a low of 5.1% in September 2020...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment